Viking Therapeutics is quickly emerging as one of the most promising biotech stocks in the small-cap Russell 2000 index. With Wall Street analysts projecting a potential upside of ...

We recently published a list of Investors Are Gobbling Up Shares of These 10 Firms. In this article, we are going to take a ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

According to TipRanks.com, Ulz is a 1-star analyst with an average return of -0.7% and a 42.5% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Aardvark Therapeutics, Inc., ...

Here's the list of options activity happening in today's session: These itemized elaborations have been created using the accompanying table.

Meeting to be held in Montreal, Canada on June 18 hosted by B. Riley. Published first on TheFly – the ultimate source for real-time, market-moving ...

We recently published a list of Jim Cramer Nailed These 11 Stock Predictions. In this article, we are going to take a look at ...

NVO advances obesity pipeline with CagriSema and Amycretin while expanding through major deals amid rising competition.

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies are ...

Viking Therapeutics, Inc. (VKTX) closed the most recent trading day at $26.61, moving +1.88% from the previous trading session. The stock's change was more than the S&P 500's daily gain of 0.58%.